Becton, Dickinson and Company (NYSE:BDX – Get Free Report) has been given an average rating of “Moderate Buy” by the eighteen research firms that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, eight have assigned a hold recommendation, eight have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $197.47.
A number of research firms have recently issued reports on BDX. Piper Sandler raised their target price on shares of Becton, Dickinson and Company from $175.00 to $200.00 and gave the stock a “neutral” rating in a research note on Friday, November 6th. Bank of America upped their price target on shares of Becton, Dickinson and Company from $185.00 to $200.00 and gave the company a “neutral” rating in a research note on Monday, August 31st. JPMorgan Chase & Co. increased their price target on shares of Becton, Dickinson and Company from $170.00 to $202.00 and gave the company a “neutral” rating in a report on Friday, November 6th. Wolfe Research began coverage on shares of Becton, Dickinson and Company in a research report on Tuesday, October 20th. They set an “outperform” rating for the company. Finally, UBS Group began coverage on Becton, Dickinson and Company in a report on Tuesday, July 28th. They set a “buy” rating and a $190.00 price objective for the company.
Check Out Our Latest Report on BDX
Insider Activity at Becton, Dickinson and Company
In related news, EVP Michael Feld sold 165 shares of the business’s stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $188.49, for a total value of $31,100.85. Following the completion of the sale, the executive vice president directly owned 19,720 shares in the company, valued at $3,717,022.80. The trade was a 0.83% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas Polen, Jr. sold 2,993 shares of the company’s stock in a transaction on Thursday, November 5th. The shares were sold at an average price of $210.00, for a total value of $628,530.00. Following the completion of the transaction, the chief executive officer directly owned 110,163 shares in the company, valued at approximately $23,134,230. This represents a 2.65% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 3,310 shares of company stock valued at $688,650. 0.40% of the stock is currently owned by insiders.
Institutional Investors Weigh In On Becton, Dickinson and Company
A number of institutional investors have recently modified their holdings of BDX. Maryland Capital Advisors Inc. raised its stake in Becton, Dickinson and Company by 13,900.0% in the 3rd quarter. Maryland Capital Advisors Inc. now owns 140 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 139 shares in the last quarter. Trifecta Capital Advisors LLC grew its position in shares of Becton, Dickinson and Company by 59.0% during the 3rd quarter. Trifecta Capital Advisors LLC now owns 167 shares of the medical instruments supplier’s stock worth $30,000 after purchasing an additional 62 shares in the last quarter. Meeder Asset Management Inc. grew its position in shares of Becton, Dickinson and Company by 152.2% during the 1st quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier’s stock worth $27,000 after purchasing an additional 102 shares in the last quarter. DiPaolo Financial Group Inc. bought a new position in shares of Becton, Dickinson and Company during the third quarter worth approximately $32,000. Finally, Main Street Group LTD bought a new position in shares of Becton, Dickinson and Company during the first quarter worth approximately $29,000. Institutional investors own 86.97% of the company’s stock.
Becton, Dickinson and Company Trading Down 0.3%
Shares of Becton, Dickinson and Company stock opened at $215.77 on Friday. The company has a debt-to-equity ratio of 0.54, a current ratio of 0.87 and a quick ratio of 0.54. The business has a fifty day simple moving average of $192.26 and a two-hundred day simple moving average of $170.70. Becton, Dickinson and Company has a 1 year low of $140.11 and a 1 year high of $220.36. The company has a market capitalization of $59.45 billion, a price-to-earnings ratio of 52.12, a P/E/G ratio of 3.63 and a beta of 0.22.
Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last released its quarterly earnings data on Thursday, November 5th. The medical instruments supplier reported $4.15 EPS for the quarter, beating the consensus estimate of $4.07 by $0.08. The firm had revenue of $5.27 billion for the quarter, compared to the consensus estimate of $5.11 billion. Becton, Dickinson and Company had a net margin of 5.66% and a return on equity of 14.90%. The company’s quarterly revenue was up 5.4% on a year-over-year basis. During the same period in the previous year, the company earned $3.96 earnings per share. Research analysts forecast that Becton, Dickinson and Company will post 13.21 EPS for the current year.
Becton, Dickinson and Company Increases Dividend
The company also recently announced a quarterly dividend, which will be paid on Thursday, December 31st. Stockholders of record on Thursday, December 10th will be paid a dividend of $1.06 per share. This represents a $4.24 dividend on an annualized basis and a dividend yield of 2.0%. This is an increase from Becton, Dickinson and Company’s previous quarterly dividend of $1.05. The ex-dividend date is Thursday, December 10th. Becton, Dickinson and Company’s dividend payout ratio is 101.45%.
Becton, Dickinson and Company declared that its Board of Directors has authorized a share buyback program on Thursday, November 5th that permits the company to buy back 10,000,000 outstanding shares. This buyback authorization permits the medical instruments supplier to reacquire up to 3.6% of its shares through open market purchases. Stock buyback programs are often a sign that the company’s leadership believes its stock is undervalued.
Becton, Dickinson and Company Company Profile
Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops and manufactures products used in healthcare, clinical laboratories and life sciences research. Founded in 1897, the company has a long history of producing medical devices and supplies. BD’s products include syringes, needles, infusion systems and medication-management technologies, as well as equipment and supplies for collecting and processing clinical specimens. The company also provides diagnostic systems, laboratory instruments and tools used in areas such as cell analysis and biomedical research.
Featured Stories
- Five stocks we like better than Becton, Dickinson and Company
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.
